机译:HIV和/或结核分枝杆菌感染的成年人中的新结核病疫苗MVA85A的Ha期试验
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
Jenner Institute, Oxford University, Oxford, United Kingdom;
Jenner Institute, Oxford University, Oxford, United Kingdom;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
Aeras, Rondebosch, South Africa;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
Jenner Institute, Oxford University, Oxford, United Kingdom;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health,;
Jenner Institute, Oxford University, Oxford, United Kingdom;
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health;
tuberculosis; HIV-1; vaccine; MVA85A; clinical trial;
机译:接种BC9的健康成年人中单独使用FP9载体的候选结核病疫苗(FP85A)和与候选疫苗MVA85A的安全性和免疫原性I期临床试验
机译:在BCG疫苗接种的健康成年人中,单独和与候选疫苗MVA85A一起使用FP9载体的候选结核病疫苗(FP85A)的安全性和免疫原性:I期临床试验
机译:候选结核疫苗MVA85A在感染HIV-1的健康成人中的安全性,免疫原性和功效:一项随机,安慰剂对照的2期临床试验
机译:使用分枝杆菌SSP。 Paratuberculosis 70 kd热休克蛋白作为亚基疫苗靶向牛副植物
机译:分枝杆菌的先天性杀伤逃避(ike)基因的表征及其在结核分枝杆菌疫苗中的应用
机译:在艾滋病毒和/或结核分枝杆菌感染的成年人中新结核病疫苗MVA85A的IIa期试验
机译:在感染了HIV和/或结核分枝杆菌的成人中,新的结核疫苗MVA85A的IIa期试验。